Vyvanse is a prescription medicine which is used to treat attention deficit hyperactivity disorder (ADHD) in adults and in children who are at least 6 years old.
Shire has filed a case against Roxane in the US District Court for the District of New Jersey and against Watson in the US District Court for the Central District of California.
The lawsuit was filed in connection with the submission of abbreviated new drug applications (ANDAs) by Roxane and Watson seeking marketing approval for the generic versions of almost all approved doses of Vyvanse with the US Food and Drug Administration (FDA).